Table 2.
Study | Phase | Checkpoint inhibitor | Chemotherapy | Population | No. of patients | pCR (ypT0/is and ypN0) |
---|---|---|---|---|---|---|
I-SPY 243 | 2 | Pembrolizumab | Paclitaxel or paclitaxel/pembro followed by doxorubicin/cyclophosphamide |
TNBC ; HR+/HER2- ; PD-L1 unselected ; tumour size > 2.5 cm; mammaprint high risk (nodal involvement in 37.7% pembro, 43.9% control) |
69 pembro, 180 control |
TNBC: 60% pembro vs. 20% controla HR+/HER2-: 34% pembro vs. 13% controla |
KEYNOTE-17341 | 1b | Pembrolizumab |
A: pembro followed by pembro + nab-paclitaxel followed by pembro + doxorubicin/cyclophosphamide . B: pembro followed by pembro + nab-paclitaxel + carboplatin followed by pembro + doxorubicin/cyclophosphamide |
TNBC ; PD-L1 unselected ; locally advanced (primary tumour stage ≥T2 in 90%, nodal involvement in 75%) |
20 |
Cohort A, 60%; Cohort B, 90% |
Pusztai et al.42 | 1 | MEDI4736 | MEDI4736 + nab-paclitaxel followed by dose dense doxorubicin/cyclophosphamide |
TNBC ; PD-L1 unselected; stage I-III (primary tumour stage ≥T2 in 57%, nodal involvement in 57%) |
7 | 71.4% |
Recently presented studies of anti-PD1/PD-L1 agents in neoadjuvant breast cancer therapy.
pCR pathological complete response.
aEstimated pCR